UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Annals of oncology, 2015-09, Vol.26 (9), p.1883-1889

2015

Volltextzugriff (PDF)

Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer

Drug development and industrial pharmacy, 2017-08, Vol.43 (8), p.1244-1253

2017

Volltextzugriff (PDF)

Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation

Carbohydrate polymers, 2015-12, Vol.134, p.547-556

2015

Volltextzugriff (PDF)

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Journal of clinical oncology, 2017-02, Vol.35 (4), p.412-420

2017

Volltextzugriff (PDF)

Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash

European journal of cancer (1990), 2016-03, Vol.55, p.131-139

2016

Volltextzugriff (PDF)

Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy

Journal of medicinal chemistry, 2019-04, Vol.62 (7), p.3171-3183

2019

Volltextzugriff (PDF)

Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab

Biomedicine & pharmacotherapy, 2020-05, Vol.125, p.109861, Article 109861

2020

Volltextzugriff (PDF)

EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis

Journal of investigative dermatology, 2024-04

2024

Volltextzugriff (PDF)

Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way

Journal of experimental & clinical cancer research, 2023-07, Vol.42 (1), p.179-179, Article 179

2023

Volltextzugriff (PDF)

Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer

Biomaterials, 2017-11, Vol.145, p.56-71

2017

Volltextzugriff (PDF)

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

International journal of cancer, 2017-06, Vol.140 (12), p.2805-2819

2017

Volltextzugriff (PDF)

Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer

European journal of pharmaceutics and biopharmaceutics, 2024-08, Vol.201, p.114386, Article 114386

2024

Volltextzugriff (PDF)

Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability

Carbohydrate polymers, 2016-02, Vol.137, p.339-349

2016

Volltextzugriff (PDF)

Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats

Biological and Pharmaceutical Bulletin, 2021/08/01, Vol.44(8), pp.1050-1059

2021

Volltextzugriff (PDF)

Inhibition of ABCB1 and ABCG2 at the Mouse Blood–Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

Molecular pharmaceutics, 2019-03, Vol.16 (3), p.1282-1293

2019

Volltextzugriff (PDF)

Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer

Acta biomaterialia, 2018-08, Vol.76, p.257-274

2018

Volltextzugriff (PDF)

EGFR and NF-κB: partners in cancer

Trends in molecular medicine, 2015-06, Vol.21 (6), p.385-393

2015

Volltextzugriff (PDF)

Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma

Angewandte Chemie International Edition, 2018-11, Vol.57 (46), p.15040-15044

International ed. in English, 2018

Volltextzugriff (PDF)

Serially pH-Modulated Hydrogels Based on Boronate Ester and Polydopamine Linkages for Local Cancer Therapy

ACS applied materials & interfaces, 2021-01, Vol.13 (2), p.2189-2203

2021

Volltextzugriff (PDF)

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Annals of oncology, 2017-02, Vol.28 (2), p.278-284

2017

Volltextzugriff (PDF)

Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential

International journal of biological macromolecules, 2019-10, Vol.139, p.1304-1316

2019

Volltextzugriff (PDF)

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer

Pharmacological research, 2023-05, Vol.191, p.106739-106739, Article 106739

2023

Volltextzugriff (PDF)

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Cochrane database of systematic reviews, 2016-05 (5), p.CD010383

2016

Volltextzugriff (PDF)

Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy

Carbohydrate polymers, 2020-10, Vol.245, p.116407, Article 116407

2020

Volltextzugriff (PDF)

The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis

Gene, 2022-03, Vol.816, p.146173-146173, Article 146173

2022

Volltextzugriff (PDF)

1 – 25 von 5.736

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.100)
Mit Volltextzugriff
(4.912)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

14 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(4.655)
Life Sciences & Biomedicine
(4.390)
Humans
(4.345)
Erlotinib
(3.005)
Oncology
(2.844)
Erlotinib Hydrochloride
(2.718)
Lung Neoplasms - Drug Therapy
(2.270)
Female
(2.023)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(1.924)
Male
(1.761)
Middle Aged
(1.512)
Quinazolines - Therapeutic Use
(1.449)
Aged
(1.391)
Protein Kinase Inhibitors - Therapeutic Use
(1.283)
Mutation
(1.260)
Receptor, Epidermal Growth Factor - Antagonists & Inhibitors
(1.259)
Lung Cancer
(1.196)
Antineoplastic Agents - Therapeutic Use
(1.118)
Lung Neoplasms - Pathology
(1.088)
Lung Neoplasms - Genetics
(1.009)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(4.510)
EZB Electronic Journals Library
(3.050)
IngentaConnect
(2.569)
Journals@Ovid Full Text
(1.992)
IngentaConnect Journals
(1.626)
Elsevier ScienceDirect Journals Complete
(1.061)
Publisher or Other Site
(1.001)
Springer Online Journals
(696)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(630)
Wiley Online Library
(466)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(405)
Taylor & Francis Journals
(363)
Taylor & Francis Journals
(288)
Nexis Uni
(280)
Wiley Online Library Full Collection 2018
(269)
Taylor & Francis Online
(187)
Springer Nature - Connect here FIRST to enable access
(186)
Oxford Journals
(95)
SAGE Journals
(82)
Oxford Journals 2020 Medicine
(81)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(210)
Journal Of Thoracic Oncology
(192)
Clinical Cancer Research
(147)
Journal Of Clinical Oncology
(144)
Clinical Lung Cancer
(122)
Plos One
(89)
Cancer Chemotherapy And Pharmacology
(78)
Oncotarget
(76)
Anticancer Research
(72)
Cancer Research
(72)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer

Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash

Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy

Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab

EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis

Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way

Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer

Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability

Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats

Inhibition of ABCB1 and ABCG2 at the Mouse Blood–Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer

EGFR and NF-κB: partners in cancer

Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma

Serially pH-Modulated Hydrogels Based on Boronate Ester and Polydopamine Linkages for Local Cancer Therapy

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy

The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis

Suchergebnisse filtern